Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universita Degli Studi Di Modena E Reggio Emilia |
| Country | Italy |
| Start Date | Nov 01, 2023 |
| End Date | Oct 31, 2028 |
| Duration | 1,826 days |
| Number of Grantees | 18 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101080189 |
The ARISTOTELES project aims to build a multinational harmonized data platform to develop and implement novel artificial intelligence (AI) approaches for management of complex diseases, where progression and manifestations of comorbidities are via multiple interacting pathways.
We aim to apply our novel approach to a population of great need due to atrial fibrillation (AF), but our outputs can be extended to other complex diseases with multimorbidity.
By integrating AIs into clinical practice, our platform will form a backbone for acceptable, responsible, and respectful uses of patient/participant data to develop and validate novel trustworthy AI tools for more personalized risk assessment and management.
This represents a paradigm shift in AF treatment, moving from a focus on individual risk factors and selected outcomes (eg. stroke) to a holistic approach, underpinning timely diagnostic and therapeutic interventions to reduce disease progression, disability, hospitalizations and mortality, as well as improve patient adherence to lifestyle modifications, medications, and other treatment regimens.ARISTOTELES will be delivered through 8 inter-linking work-packages (WPs): WP1 is study management/coordination.
WP2 provides the ethical/legal requirements for the development of a trustworthy AI.
WP3 addresses stakeholder understanding of AI, needs assessment, and engagement in all the phases of the AI development.
In WP4, granular data on genotype and phenotype characteristics, are harmonized from different datasets into a common platform. In WP5, AI algorithms/tools are developed and connected to an interactive output interface for patients and clinicians. In WP6, we test the AI tool developed in WP5 in a clinical trial simulation (in silico trial).
In WP7 a multicenter randomized trial runs across multiple countries including both primary care and secondary care. WP7 and WP8 drive the clinical implementation and dissemination of results.
The University of Manchester; Iotic Solutions Sl; Gers Sas; Panepistimio Kritis; Liverpool John Moores University; Moverim Srl; Universidad de Murcia; Universidade de Coimbra; Universitetet I Oslo; The University of Liverpool; Idoven 1903 Sl; Datariver Srl; University College London; Aimes Management Services Limited; Universita Degli Studi Di Modena E Reggio Emilia; Aalborg Universitet; Universitatea de Medicina Si Farmacie Carol Davila Din Bucuresti; Fondazione Per Il Tuo Cuore Onlus
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant